je.st
news
Tag: fda approves
FDA Approves Mercks GRASTEK (Timothy Grass Pollen Allergen Extract) Sublingual Tablet as Immunotherapy to Treat Grass Pollen-Induced Allergic Rhinitis with or without Conjunctivitis in Children and Adults
2014-04-14 23:59:00| Merck.com - Corporate News
Dateline City: WHITEHOUSE STATION, N.J. GRASTEK is the Only FDA Approved Sublingual Allergy Immunotherapy Tablet Indicated for Children as Young as 5 Years of Age WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved GRASTEK (Timothy Grass Pollen Allergen Extract) Tablet for Sublingual Use [2800 Bioequivalent Allergy Units (BAU)]. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orRobert Consalvo, 908-423-6595orInvestor:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: without
children
adults
treat
U.S. FDA approves Celgene drug for psoriatic arthritis
2014-03-22 01:04:03| Biotech - Topix.net
U.S. health regulators on Friday approved a Celgene Corp drug to treat psoriatic arthritis, a type of arthritis associated with the skin disease psoriasis that causes joint pain, stiffness and swelling.
Tags: drug
arthritis
fda
approves
FDA Approves Merck's NOXAFIL (posaconazole) Injection (18 mg/mL) for Intravenous Use
2014-03-15 04:54:54| Biotech - Topix.net
Merck , known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has approved NOXAFIL injection , a new formulation of NOXAFIL for intravenous use.
Tags: use
injection
fda
approves
FDA Approves Mercks NOXAFIL (posaconazole) Injection (18 mg/mL) for Intravenous Use
2014-03-14 18:40:00| Merck.com - Product News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has approved NOXAFIL (posaconazole) injection (18 mg/ mL), a new formulation of NOXAFIL for intravenous (IV) use. Mercks antifungal agent is also marketed as NOXAFIL (100 mg) delayed-release tablets and NOXAFIL (40 mg/mL) oral suspension. Language: English Contact: MerckMedia:Pam Eisele, (267) 305-3558Robert Consalvo, (908) 423-6595orInvestor:Carol Ferguson, (908) 423-4465Justin Holko, (908) 423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: use
injection
fda
approves
FDA approves Bristol-Myers drug for rare body fat disorder
2014-02-25 20:20:03| Biotech - Topix.net
Bristol-Myers Squibb Co said the U.S. Food and Drug Administration approved its drug to treat rare and potentially fatal disorders involving loss of body fat.
Sites : [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] next »